GANX Gain Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819411 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.3%
TTM EPS YoY31.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-223.9%
ROA-148.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.03x
Current ratio5.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $10.21M | $10.79M |
| SG&A expense | $8.50M | $9.56M |
| Operating income | -$18.71M | -$20.35M |
| Pretax income | -$19.30M | -$19.87M |
| Income tax | $861,118 | $536,815 |
| Net income | -$20.16M | -$20.41M |
| EBITDA | -$18.62M | -$20.27M |
| EPS (basic) | -0.61 | -0.89 |
| EPS (diluted) | -0.61 | -0.89 |
| Weighted avg. shares (diluted) | 32.97M | 22.88M |
| Balance sheet | ||
| Cash & equivalents | $20.84M | $10.42M |
| Current assets | $22.24M | $11.60M |
| PP&E, net | $74,916 | $103,619 |
| Intangibles | $102,837 | — |
| Total assets | $22.82M | $12.12M |
| Current liabilities | $3.35M | $3.91M |
| Short-term debt | $100,869 | $110,177 |
| Long-term debt | $300,084 | $328,327 |
| Total debt | $400,953 | $438,504 |
| Total liabilities | $4.25M | $4.78M |
| Shareholders' equity | $18.56M | $7.34M |
| Net debt | -$20.44M | -$9.98M |
| Shares outstanding | 42.07M | 27.13M |
| Cash flow statement | ||
| Operating cash flow | -$18.47M | -$18.87M |
| Capital expenditure | — | $22,493 |
| Free cash flow | — | -$18.90M |
| Investing cash flow | — | $4.98M |
| Financing cash flow | $28.45M | $13.01M |
| Depreciation & amortization | $94,046 | $84,071 |
| Stock-based compensation | $1.80M | $2.39M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.